vs
Side-by-side financial comparison of Lumentum Holdings Inc. (LITE) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $665.5M, roughly 1.2× Lumentum Holdings Inc.). Insulet Corporation runs the higher net margin — 13.0% vs 11.8%, a 1.2% gap on every dollar of revenue. On growth, Lumentum Holdings Inc. posted the faster year-over-year revenue change (65.5% vs 31.2%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $43.1M). Over the past eight quarters, Lumentum Holdings Inc.'s revenue compounded faster (34.8% CAGR vs 33.2%).
JDS Uniphase Corporation (JDSU) was an American company that designed and manufactured products for optical communications networks, communications test and measurement equipment, lasers, optical solutions for authentication and decorative applications, and other custom optics. It was headquartered in Milpitas, California. In August 2015, JDSU split into two different companies – Viavi Solutions and Lumentum Holdings.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
LITE vs PODD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $665.5M | $783.7M |
| Net Profit | $78.2M | $101.6M |
| Gross Margin | 36.1% | 72.6% |
| Operating Margin | 9.7% | 18.7% |
| Net Margin | 11.8% | 13.0% |
| Revenue YoY | 65.5% | 31.2% |
| Net Profit YoY | 228.4% | 0.9% |
| EPS (diluted) | $0.89 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $665.5M | $783.7M | ||
| Q3 25 | $533.8M | $706.3M | ||
| Q2 25 | $480.7M | $649.1M | ||
| Q1 25 | $425.2M | $569.0M | ||
| Q4 24 | $402.2M | $597.5M | ||
| Q3 24 | $336.9M | $543.9M | ||
| Q2 24 | $308.3M | $488.5M | ||
| Q1 24 | $366.5M | $441.7M |
| Q4 25 | $78.2M | $101.6M | ||
| Q3 25 | $4.2M | $87.6M | ||
| Q2 25 | $213.3M | $22.5M | ||
| Q1 25 | $-44.1M | $35.4M | ||
| Q4 24 | $-60.9M | $100.7M | ||
| Q3 24 | $-82.4M | $77.5M | ||
| Q2 24 | $-252.5M | $188.6M | ||
| Q1 24 | $-127.0M | $51.5M |
| Q4 25 | 36.1% | 72.6% | ||
| Q3 25 | 34.0% | 72.2% | ||
| Q2 25 | 33.3% | 69.7% | ||
| Q1 25 | 28.8% | 71.9% | ||
| Q4 24 | 24.8% | 72.1% | ||
| Q3 24 | 23.1% | 69.3% | ||
| Q2 24 | 16.6% | 67.7% | ||
| Q1 24 | 16.2% | 69.5% |
| Q4 25 | 9.7% | 18.7% | ||
| Q3 25 | 1.3% | 16.7% | ||
| Q2 25 | -1.7% | 18.7% | ||
| Q1 25 | -8.9% | 15.6% | ||
| Q4 24 | -12.8% | 18.3% | ||
| Q3 24 | -24.5% | 16.2% | ||
| Q2 24 | -43.3% | 11.2% | ||
| Q1 24 | -31.3% | 12.9% |
| Q4 25 | 11.8% | 13.0% | ||
| Q3 25 | 0.8% | 12.4% | ||
| Q2 25 | 44.4% | 3.5% | ||
| Q1 25 | -10.4% | 6.2% | ||
| Q4 24 | -15.1% | 16.9% | ||
| Q3 24 | -24.5% | 14.2% | ||
| Q2 24 | -81.9% | 38.6% | ||
| Q1 24 | -34.7% | 11.7% |
| Q4 25 | $0.89 | $1.42 | ||
| Q3 25 | $0.05 | $1.24 | ||
| Q2 25 | $3.10 | $0.32 | ||
| Q1 25 | $-0.64 | $0.50 | ||
| Q4 24 | $-0.88 | $1.38 | ||
| Q3 24 | $-1.21 | $1.08 | ||
| Q2 24 | $-3.75 | $2.59 | ||
| Q1 24 | $-1.88 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $846.6M | $1.5B |
| Total Assets | $4.8B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $877.1M | — | ||
| Q1 25 | $866.7M | — | ||
| Q4 24 | $896.7M | — | ||
| Q3 24 | $916.1M | — | ||
| Q2 24 | $887.0M | — | ||
| Q1 24 | $870.9M | — |
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $846.6M | $1.5B | ||
| Q3 25 | $780.8M | $1.4B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $879.5M | $1.3B | ||
| Q4 24 | $872.3M | $1.2B | ||
| Q3 24 | $895.9M | $1.1B | ||
| Q2 24 | $957.3M | $998.4M | ||
| Q1 24 | $1.2B | $790.7M |
| Q4 25 | $4.8B | $3.2B | ||
| Q3 25 | $4.6B | $3.0B | ||
| Q2 25 | $4.2B | $3.5B | ||
| Q1 25 | $4.0B | $3.5B | ||
| Q4 24 | $4.0B | $3.1B | ||
| Q3 24 | $4.0B | $3.0B | ||
| Q2 24 | $3.9B | $2.9B | ||
| Q1 24 | $4.2B | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $126.7M | $183.3M |
| Free Cash FlowOCF − Capex | $43.1M | $48.2M |
| FCF MarginFCF / Revenue | 6.5% | 6.2% |
| Capex IntensityCapex / Revenue | 12.6% | 17.2% |
| Cash ConversionOCF / Net Profit | 1.62× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $-29.5M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.7M | $183.3M | ||
| Q3 25 | $57.9M | $125.7M | ||
| Q2 25 | $64.0M | $196.5M | ||
| Q1 25 | $-1.6M | $63.8M | ||
| Q4 24 | $24.3M | $147.7M | ||
| Q3 24 | $39.6M | $98.5M | ||
| Q2 24 | $35.5M | $96.5M | ||
| Q1 24 | $-7.0M | $87.6M |
| Q4 25 | $43.1M | $48.2M | ||
| Q3 25 | $-18.3M | $100.1M | ||
| Q2 25 | $10.1M | $177.9M | ||
| Q1 25 | $-64.4M | $51.5M | ||
| Q4 24 | $-15.9M | $94.1M | ||
| Q3 24 | $-34.5M | $71.8M | ||
| Q2 24 | $10.9M | $74.0M | ||
| Q1 24 | $-26.6M | $65.5M |
| Q4 25 | 6.5% | 6.2% | ||
| Q3 25 | -3.4% | 14.2% | ||
| Q2 25 | 2.1% | 27.4% | ||
| Q1 25 | -15.1% | 9.1% | ||
| Q4 24 | -4.0% | 15.7% | ||
| Q3 24 | -10.2% | 13.2% | ||
| Q2 24 | 3.5% | 15.1% | ||
| Q1 24 | -7.3% | 14.8% |
| Q4 25 | 12.6% | 17.2% | ||
| Q3 25 | 14.3% | 3.6% | ||
| Q2 25 | 11.2% | 2.9% | ||
| Q1 25 | 14.8% | 2.2% | ||
| Q4 24 | 10.0% | 9.0% | ||
| Q3 24 | 22.0% | 4.9% | ||
| Q2 24 | 8.0% | 4.6% | ||
| Q1 24 | 5.3% | 5.0% |
| Q4 25 | 1.62× | 1.80× | ||
| Q3 25 | 13.79× | 1.43× | ||
| Q2 25 | 0.30× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LITE
| Components | $443.7M | 67% |
| Systems | $221.8M | 33% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
